Inhibitors of copper-containing amine oxidases

摘要

The use of an oxadiazine compound of Formula I or a form of the oxadiazine compound of Formula I selected from the list consisting of a tautomer, isomer, a pharmaceutically acceptable solvate, a pharmaceutically acceptable hydrate and a salt, for the manufacture of a pharmaceutical preparation for inhibiting human semicarbazine-sensitive amine oxidase (SSAO). The compound may be used in the manufacture of a pharmaceutical preparation for the treatment or prevention of inflammatory disease or condition, a disease related to carbohydrate metabolism, a disease related to aberrations in adipocyte differentiation or function, a disease related to smooth muscle cell function and a vascular disease.